Systematic review: Ultra-long‐acting insulins provide modest benefit compared to NPH insulin for Type 2 DM, resulting in reduced risk of hypoglycemia but no difference in HbA1c 23 Nov, 2020 | 09:45h | UTC (Ultra‐)long‐acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus – Cochrane Library Summary: (Ultra-)long-acting insulin analogues compared with NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus